Search
Acute Myeloid Leukemia
go.drugbank.com/conditions/DBCOND0029883Drugs: Azacitidine · Cedazuridine · Cyclophosphamide · Cytarabine · Decitabine · Doxorubicin +9 moreSynonyms: Acute myeloid leukemia, no ICD-O subtype (morphologic abnormality), Acute myeloid leukemia, no International Classification of Diseases for Oncology subtypeEcallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … It was discovered by phage display technology [A32017].
Categories: Analgesics, Non-NarcoticEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalEltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver. … [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma.
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalIt is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. … Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigational[L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
Etofamide
go.drugbank.com/drugs/DB13258ApprovedEtofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].
Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.
Categories: Antiinflammatory and Antirheumatic Products, Non-SteroidsFerric pyrophosphate citrate
go.drugbank.com/drugs/DB13995ApprovedThe ferric ion is strongly complexed by pyrophosphate and citrate.[A31979] FPC is categorized in Japan as a second class OTC drug. … [L1420] This category is given to drugs with ingredients that in rare cases may cause health problems requiring hospitalization or worst.[L1419] It is also FDA approved since 2015.[FDA label]
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure … [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]